Arbutus Biopharma Corp (ABUS) Net margin 2016–2025
Arbutus Biopharma Corp (ABUS) net profit margin by fiscal year — reported net income divided by reported revenue.
-237.9%FY2025 · since FY2016: -25765.5% → -237.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -237.9% | +895.2 pp |
| FY2024 | -1133.0% | -731.5 pp |
| FY2023 | -401.6% | -223.6 pp |
| FY2022 | -178.0% | +515.9 pp |
| FY2021 | -693.9% | +228.1 pp |
| FY2020 | -922.0% | +1635.4 pp |
| FY2019 | -2557.4% | -1597.6 pp |
| FY2018 | -959.8% | -170.9 pp |
| FY2017 | -788.9% | +24976.6 pp |
| FY2016 | -25765.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice